RESUMEN
PURPOSE: To assess the prevalence of autoimmune diseases (ADs) associated with ocular cicatricial pemphigoid (OCP) and analyze clinical, laboratory, and treatment associations between these entities. METHODS: A multicentre cross-sectional study of patients with an OCP diagnosis. The population was divided into two groups according to their association with other ADs or not. Clinical, laboratory and treatment variables were described and compared between groups. A multivariable logistic regression analysis was performed to identify variables that could suggest the association between OCP and ADs. RESULTS: Eighty-eight patients were recruited, with a mean age at diagnosis of 64.3 years (SD 11.9). Biopsy was performed in 86.8% of the patients. There was a median delay of 2 years from the onset of symptoms to diagnosis. Extraocular involvement was evidenced in 11.5%. The group associated with ADs included 24 patients (27.3%). The most prevalent diagnosis was Sjögren´s syndrome. Hypergammaglobulinemia was associated with ADs and OCP, adjusted for age, sex, smoking, skin and mucosal involvement, and erythrocyte sedimentation rate (OR 8.7; 95%CI 1.6-46.8; p = 0.012). CONCLUSIONS: Due to OCP's autoimmune nature, it could coexist with other ADs. This study observed that more than a quarter of the population presented with this association, and hypergammaglobulinemia could suggest it.
Asunto(s)
Enfermedades Autoinmunes , Penfigoide Benigno de la Membrana Mucosa , Síndrome de Sjögren , Humanos , Persona de Mediana Edad , Penfigoide Benigno de la Membrana Mucosa/complicaciones , Penfigoide Benigno de la Membrana Mucosa/diagnóstico , Estudios Transversales , Hipergammaglobulinemia , Enfermedades Autoinmunes/complicaciones , Enfermedades Autoinmunes/diagnóstico , Enfermedades Autoinmunes/epidemiologíaRESUMEN
BACKGROUND: Most epidemiologic studies involving severe granulomatosis with polyangiitis (SGPA) patients have investigated populations from the northern hemisphere, whereas few studies have been conducted in South America. None of the South American studies have differentiated between localized GPA and SGPA. PURPOSE: The present study was designed to describe a cohort of Argentinean patients who were diagnosed with SGPA and to compare this cohort with previously well-described cohorts. METHODS: We performed a retrospective study that included 37 consecutive SGPA patients who were seen at 2 tertiary centers in Buenos Aires. RESULTS: Nineteen patients (51.3%) were male, and 18 patients (49.7%) were female. The mean age at the onset of symptoms was 48.5 ± 12.01 years. Antineutrophil cytoplasmic antibody (ANCA) was detected in 34 patients (91.89%): 32 patients (86.48%) had a cytoplasmic staining pattern, whereas 2 patients (5.40%) had a perinuclear pattern. Three patients were ANCA-negative. Twenty-four patients (64%) achieved remission, and 7 patients (19%) had response as defined by at least 50% reduction in the disease activity score. Nineteen relapses were observed in 12 patients, and 2 of the relapses were fatal. Overall, there were 14 deaths (37.83%). CONCLUSIONS: The present series demonstrated that Argentinean patients have similar demographics, clinical manifestations, and outcomes as the cohorts from the northern hemisphere. There was less granulomatous organ involvement (ear/nose/throat, lung granulomas) in the present cohort compared with other series.
Asunto(s)
Ciclofosfamida/uso terapéutico , Glucocorticoides/uso terapéutico , Granulomatosis con Poliangitis/diagnóstico , Granulomatosis con Poliangitis/tratamiento farmacológico , Inmunosupresores/uso terapéutico , Adulto , Anticuerpos Anticitoplasma de Neutrófilos/sangre , Argentina , Estudios de Cohortes , Quimioterapia Combinada , Femenino , Técnica del Anticuerpo Fluorescente , Granulomatosis con Poliangitis/mortalidad , Humanos , Masculino , Persona de Mediana Edad , Inducción de Remisión , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
OBJECTIVE: To assess the association between the HLA-B*51 allele and Behçet Disease (BD) in Argentinean patients. METHODS: We enrolled 34 consecutive Argentinean patients with definitive diagnosis of BD between October 2016 and March 2017. None of the patients had the HLA-B*51 allele determined at study entry. Unrelated controls (n=240) were randomly obtained from the national cadaveric donor database. Demographic and clinical features of the patients were recorded by attending physicians through a questionnaire. RESULTS: Mean age of cases was 42 years old. Nineteen (55.8%) were male, and the mean age at diagnosis was 35 years old; twenty (58.8%) were Mestizos, 8 (23.5%) were Caucasian, and 6 (17.6%) were Amerindians. Thirteen (38.2%) of 34 cases were HLA-B*51 allele positive; 11 were heterozygous and 2 homozygous for the allele. Thirty-four (14.2%) of 240 controls were positive for the HLA-B*51 allele. The association between BD and HLA-B*51 allele was greater than that of control group (OR=3.75; p=0.0012). CONCLUSIONS: The HLA-B*51 allele is strongly associated with BD in Argentinean patients. Our finding is consistent with previous studies indicating that the HLA-B*51 allele is an important susceptibility gene in BD regardless the geographical region and ethnicity.
Asunto(s)
Alelos , Síndrome de Behçet/genética , Antígeno HLA-B51/genética , Adulto , Argentina , Estudios de Casos y Controles , Femenino , Humanos , Masculino , Persona de Mediana EdadRESUMEN
Diversas etiologías pueden desencadenar a las vasculitis ANCA (anticuerpos anticitoplasma de neutrófilo). Entre ellas se encuentran las neoplasias hematológicas, como los linfomas no Hodgkin, que pueden asociarse con diferentes autoanticuerpos y manifestaciones reumatológicas. Es esencial sospechar estas causas secundarias si la enfermedad tiene un curso crónico con respuesta tórpida al tratamiento. En el presente artículo se reporta un caso inusual de asociación entre granulomatosis eosinofílica con poliangeitis y linfoma no Hodgkin de bajo grado de agresividad.
Diverse etiologies can trigger ANCA (antineutrophil cytoplasmic antibodies) vasculitis. These include hematological neoplasms, such as non-Hodgkin lymphomas, which can be associated with different autoantibodies and rheumatological manifestations. These secondary causes are essential to suspect if the disease has a chronic course with a poor response to treatment. In this article, we report an unusual association between eosinophilic granulomatosis with polyangiitis and low-grade non-Hodgkin lymphoma.
Asunto(s)
Síndrome de Churg-Strauss , Granulomatosis LinfomatoideRESUMEN
BACKGROUND: The general consensus is that for patients with EGPA with poor prognosis, intensive therapy with both GC and CF is indicated. The maintenance of remission is made with GC and AZA. A considerable number of patients with EGPA are refractory to first line therapy, experience dose-limiting side effects or relapse. In clinical trials, RTX was effective for the treatment of ANCA-associated vasculitis. However, patients with a diagnosis of EGPA were not included. OBJECTIVE: to review and analyze the published literature regarding the use of RTX in the treatment of EGPA. METHODS: The literature search was performed in MEDLINE and LILACS from 1965 and 1986 respectively until february 2014. RESULTS: 27 patients were included. RTX treatment was due to refractory disease (n=20), relapse (n=5) and with newly diagnosed (n=2). The affected organs were the lungs, peripheral nervous system, kidney and the eyes. Sixteen patients had clinical remission and 8 patients had clinical response. CONCLUSIONS: RTX was effective and well tolerated for the treatment of EGPA.
Asunto(s)
Síndrome de Churg-Strauss/tratamiento farmacológico , Factores Inmunológicos/uso terapéutico , Rituximab/uso terapéutico , Humanos , Resultado del TratamientoRESUMEN
OBJECTIVE: To investigate the prevalence and associations with clinical manifestations of anti- P ribosomal antibodies in patients with juvenile-onset and adult-onset systemic lupus erythematosus (SLE). METHODS: Clinical and serological data of 30 patients with juvenile-onset SLE (age at onset younger than 16 years old) were compared with data of 92 patients with adult-onset SLE. Symptoms occurring during the entire disease course were considered. Anti- P ribosomal antibodies were tested by ELISA. RESULTS: Anti- P ribosomal antibodies were found significantly more often in pediatric-onset SLE patients (26.7% vs. 6.5%; OR=5.21 [CI95%=1.6-16.5], p=0.003). Alopecia (OR=10.11, CI 95%=1.25-97) and skin rash (non discoid) (OR=4.1, CI 95%=1.25-13.89) were significantly associated with anti- P ribosomal antibodies. CONCLUSION: Anti-ribosomal P antibodies are more often found in patients with juvenile SLE. Alopecia and skin rash were the only clinical manifestations associated to anti-ribosomal P antibodies.
Asunto(s)
Autoanticuerpos/sangre , Lupus Eritematoso Sistémico/inmunología , Fosfoproteínas/inmunología , Proteínas Ribosómicas/inmunología , Adolescente , Adulto , Edad de Inicio , Biomarcadores/sangre , Niño , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Lupus Eritematoso Sistémico/diagnóstico , MasculinoRESUMEN
We investigated the relationship between the 4G/5G plasminogen activator inhibitor (PAI-1) and -308 A/G tumor necrosis factor-α (TNF-α) polymorphisms and the clinical and biochemical features of systemic lupus erythematosus (SLE) in an Argentinean patient cohort. A total of 402 patients were studied, including 179 SLE patients and 223 healthy individuals. PCR-RLFP was used to determine the genotypes of the 4G/5G PAI-1 and -308 A/G TNF-α polymorphisms. SLE patients with lupus nephritis (LN) (n = 86) were compared with patients without LN (n = 93). Additionally, LN patients were divided into proliferative LN and non-proliferative LN groups according to the results of the renal biopsies. No significant differences were noted in the genotype distributions or allele frequencies of these TNF-α and PAI-1 polymorphisms between SLE patients and controls. There were higher numbers of criteria for SLE, more lupus flares and higher damage scores in LN patients, but there were similar frequencies of anti-phospholipid antibody (APA) positivity and anti-phospholipid syndrome. No significant difference was noted for any studied variable between the proliferative LN and non-proliferative LN groups except for the presence of APA. We found no significant differences in the TNF-α and PAI-1 genotype distributions or allele frequencies between groups. We found that the -308 A/G TNF-α and 4G/5G PAI-1 polymorphisms are not associated with susceptibility to SLE in an Argentinean population. We also did not find any association between the presence of any specific allele or genotype and the development of LN in SLE patients. Finally, no association was noted between either of the two polymorphisms and the severity of renal disease.
Asunto(s)
Predisposición Genética a la Enfermedad , Nefritis Lúpica/genética , Nefritis Lúpica/inmunología , Inhibidor 1 de Activador Plasminogénico/genética , Polimorfismo Genético , Regiones Promotoras Genéticas , Factor de Necrosis Tumoral alfa/genética , Adulto , Argentina , Estudios de Cohortes , Femenino , Frecuencia de los Genes , Estudios de Asociación Genética , Genotipo , Técnicas de Genotipaje , Humanos , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Polimorfismo de Longitud del Fragmento de RestricciónRESUMEN
Systemic lupus erythematosus (SLE) is a systemic, autoimmune disorder. Monocyte chemoattractant protein 1 (MCP-1), a chemokine involved in the recruitment and migration of monocytes/macrophages, has been shown to be increased in the plasma of SLE patients. The aim of our study was to evaluate the possible association of the polymorphism -2518 of the MCP-1 gene with the risk of developing SLE, manifesting lupus nephritis (LN) and with other clinical features of SLE in an Argentinean population. A group of 171 SLE patients and 120 control subjects were examined. Genotypic and allelic frequencies of the MCP-1 -2518 A/G polymorphism showed significant differences between the SLE and the control groups (p=0.001 and p=0.01, respectively). However, the polymorphism showed no association with LN or with the other clinical variables studied. Our results suggest that the presence of the MCP-1 -2518 A/G polymorphism might be a risk factor for developing SLE in genetically predisposed individuals, but it does not seem to have a role in the evolution of the disease in the Argentinean population.
Asunto(s)
Quimiocina CCL2/genética , Lupus Eritematoso Sistémico/genética , Polimorfismo de Nucleótido Simple/genética , Adulto , Argentina/epidemiología , Argentina/etnología , Estudios de Casos y Controles , Quimiocina CCL2/sangre , Femenino , Frecuencia de los Genes , Predisposición Genética a la Enfermedad , Humanos , Lupus Eritematoso Sistémico/sangre , Nefritis Lúpica/sangre , Nefritis Lúpica/genética , Masculino , Persona de Mediana EdadAsunto(s)
Humanos , Femenino , Adulto , Embarazo , Lupus Eritematoso Sistémico , Anticuerpos MonoclonalesRESUMEN
Takayasu's arteritis (TA) is a chronic vasculitis of unknown etiology. Celiac disease (CD) is an autoimmune disease caused by the ingestion of gluten. TA and CD have been associated with many other autoimmune conditions. However, only five cases with this association have been reported. In this series, three patients with TA and CD were included; all were female, 21, 30 and 54 years old. TA clinical manifestations preceded CD diagnosis in all patients. Aortic arch branches were affected in all of them. Serologic markers were positive and a small intestine biopsy showed typical findings of CD in the three patients. Special attention should be given to this possible association because these entities may be asymptomatic; the recognition of new disease variants modifies treatment, and sometimes CD constitutes a differential diagnosis of mesenteric ischemia.
Asunto(s)
Enfermedad Celíaca/complicaciones , Arteritis de Takayasu/complicaciones , Adulto , Enfermedad Celíaca/diagnóstico , Femenino , Humanos , Persona de Mediana Edad , Arteritis de Takayasu/diagnóstico , Adulto JovenRESUMEN
La osificación heterotópica es una condición patológica que conduce al desarrollo de hueso en el tejido blando. En la piel se denomina osteoma cutis. Estas lesiones se clasifican en primarias o secundarias. Las causas secundarias constituyen el 85% y son consecuencia de enfermedades inflamatorias, infecciones, tumores, traumatismos, lesiones de médula espinal y cirugías. Si bien la osificación heterotópica es benigna e infrecuente, puede ser una enfermedad debilitante que, asociada a dolor y rigidez, provoque mayor comorbilidad en relación con la enfermedad que la desencadenó. Comunicamos el caso de un paciente que padeció osteoma cutis asociado a tuberculosis osteoarticular
Heterotopic ossification is a patologic condition that leads bone formation in soft tissue. In particular, osteoma curtis, which can be primary or secundary, occurs when ossification if found in the skin. Secondary lessions account 85% of the cases described and they are by inflammatory diseases, infections, tumors, traumas, spinal cord lesions and surgeries. Whereas heterotopic ossification is benign and rare, it may result in wasting sickness that in combination with pain and stiffness, adding comorbidity to the disease that triggers. We report here a patient suffering osteomas cutis and osteoarticular tuberculosis. (AU)
Asunto(s)
Humanos , Masculino , Adulto , Tuberculosis Osteoarticular/complicaciones , Osificación Heterotópica/diagnóstico , Osificación Heterotópica/etiología , Osteoma/clasificación , Tuberculosis Osteoarticular/tratamiento farmacológico , Osificación Heterotópica/patología , Codo/diagnóstico por imagen , Cadera/diagnóstico por imagen , Mycobacterium tuberculosis , Antituberculosos/uso terapéuticoRESUMEN
Antecedentes: Algunos pacientes con granulomatosis eosinofílica con poliangitis (EGPA) y factores de mal pronóstico son refractarios o presentan efectos adversos al tratamiento de inducción (glucocorticoides [GC] y ciclofosfamida [CF]), o recaen durante el mantenimiento (GC y azatioprina), haciendo necesaria la búsqueda de alternativas terapéuticas. En ensayos clínicos, el rituximab (RTX) demostró ser eficaz para el tratamiento de las vasculitis asociadas al ANCA; sin embargo, los pacientes con EGPA no fueron incluidos. Objetivo: Revisar y analizar la bibliografía sobre la uso de RTX para el tratamiento de la EGPA. Métodos: La búsqueda se realizó en MEDLINE y LILACS (1965 y 1986, respectivamente, hasta febrero del 2014). Resultados: Se incluyó a 27 pacientes. La indicación de RTX fue por enfermedad refractaria (n = 20), recaída (n = 5) y nuevo diagnóstico (n = 2). Los órganos afectados fueron los pulmones, el sistema nervioso periférico, el riñón y los ojos. Se observó remisión en 16 y respuesta en 8 pacientes. Conclusiones: El RTX fue eficaz y bien tolerado para el tratamiento de la EGPA (AU)
Background: The general consensus is that for patients with EGPA with poor prognosis, intensive therapy with both GC and CF is indicated. The maintenance of remission is made with GC and AZA. A considerable number of patients with EGPA are refractory to first line therapy, experience dose-limiting side effects or relapse. In clinical trials, RTX was effective for the treatment of ANCA-associated vasculitis. However, patients with a diagnosis of EGPA were not included. Objective: to review and analyze the published literature regarding the use of RTX in the treatment of EGPA. Methods: The literature search was performed in MEDLINE and LILACS from 1965 and 1986 respectively until february 2014. Results: 27 patients were included. RTX treatment was due to refractory disease (n = 20), relapse (n = 5) and with newly diagnosed (n = 2). The affected organs were the lungs, peripheral nervous system, kidney and the eyes. Sixteen patients had clinical remission and 8 patients had clinical response. Conclusions: RTX was effective and well tolerated for the treatment of EGPA (AU)
Asunto(s)
Humanos , Anticuerpos Monoclonales/uso terapéutico , Vasculitis del Sistema Nervioso Central/tratamiento farmacológico , Granuloma Eosinófilo/tratamiento farmacológico , Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos/tratamiento farmacológico , Ciclofosfamida/uso terapéutico , Glucocorticoides/uso terapéuticoRESUMEN
OBJECTIVE: To assess the association between the HLA-B*51 allele and Behçet Disease (BD) in Argentinean patients. METHODS: We enrolled 34 consecutive Argentinean patients with definitive diagnosis of BD between October 2016 and March 2017. None of the patients had the HLA-B*51 allele determined at study entry. Unrelated controls (n=240) were randomly obtained from the national cadaveric donor database. Demographic and clinical features of the patients were recorded by attending physicians through a questionnaire. RESULTS: Mean age of cases was 42 years old. Nineteen (55.8%) were male, and the mean age at diagnosis was 35 years old; twenty (58.8%) were Mestizos, 8 (23.5%) were Caucasian, and 6 (17.6%) were Amerindians. Thirteen (38.2%) of 34 cases were HLA-B*51 allele positive; 11 were heterozygous and 2 homozygous for the allele. Thirty-four (14.2%) of 240 controls were positive for the HLA-B*51 allele. The association between BD and HLA-B*51 allele was greater than that of control group (OR=3.75; p = 0.0012). CONCLUSIONS: The HLA-B*51 allele is strongly associated with BD in Argentinean patients. Our finding is consistent with previous studies indicating that the HLA-B*51 allele is an important susceptibility gene in BD regardless the geographical region and ethnicity
OBJETIVO: Evaluar la asociación entre el alelo HLA-B*51 y la enfermedad de Behçet (EB) en pacientes argentinos. MÉTODOS: Incluimos en forma consecutiva 34 pacientes argentinos con diagnóstico definitivo de EB entre los meses de octubre de 2016 y marzo de 2017. Ninguno de los pacientes tenía el alelo HLA-B*51 determinado al inicio del estudio. Los controles no relacionados (n=240) se obtuvieron al azar de la base nacional de datos de donantes cadavéricos. Las características demográficas y clínicas de los pacientes fueron registradas por los médicos asistentes a través de un cuestionario. RESULTADOS: La edad promedio de los casos fue de 42 años. Diecinueve (55,8%) fueron varones, y la edad promedio en el momento del diagnóstico fue de 35 años; 20 (58,8%) fueron mestizos, 8 (23,5%) caucásicos y 6 (17,6%) amerindios. Trece (38,2%) de los 34 casos fueron positivos para el alelo HLA-B*51; 11 de ellos fueron heterocigotas y 2 homocigotas para dicho alelo. Treinta y cuatro (14,2%) de los 240 controles fueron positivos para el alelo HLA-B*51. La asociación entre la EB y el alelo HLA-B*51 fue mayor que en el grupo control (OR=3,75; p = 0,0012). CONCLUSIONES: El alelo HLA-B*51 está fuertemente asociado con la EB en pacientes argentinos. Nuestro hallazgo es consistente con estudios previos que indican que el alelo HLA-B*51 es un gen de susceptibilidad importante en la EB independientemente de la región geográfica y la etnia
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Predisposición Genética a la Enfermedad/genética , Síndrome de Behçet/genética , Antígeno HLA-B51/genética , Estudios de Casos y Controles , ArgentinaRESUMEN
Objetivo. Determinar la prevalencia y correlación clínica de los anticuerpos antirribosomal P en lupus eritematoso sistémico (LES) juvenil y compararlos con LES del adulto. Métodos. Se incluyeron en el estudio 30 pacientes con LES juvenil y 92 pacientes con LES del adulto. Consideramos LES de comienzo juvenil a todos aquellos pacientes que comenzaron su enfermedad antes de los 16 años. Se consideraron las manifestaciones clínicas y serológicas que presentaron los pacientes desde el diagnóstico hasta el momento de inclusión en el estudio (manifestaciones acumuladas). El anticuerpo antirribosomal P fue evaluado mediante la técnica de enzimo-inmunoensayo (ELISA). Resultados. La presencia de antirribosomal P fue significativamente mayor en el grupo de pacientes con LES juvenil comparado con LES del adulto (26,7% vs. 6,5%; OR = 5,21 [IC95% = 1,6-16,5], p = 0,003). La alopecía (OR = 10,11; IC95% = 1,25-97) y rash cutáneo (no discoide) (OR = 4,1; IC95% = 1,25-13,89) fueron las únicas manifestaciones clínicas que se asociaron en forma estadísticamente significativa con la presencia del anticuerpo antirribosomal P. Conclusión. Este estudio confirma una mayor prevalencia de anticuerpos antirribosomal P en pacientes con LES juvenil. La alopecia y el rash cutáneo fueros las únicas manifestaciones clínicas asociadas a la presencia de antirribosomal P (AU)
Objective. To investigate the prevalence and associations with clinical manifestations of anti- P ribosomal antibodies in patients with juvenile-onset and adult-onset systemic lupus erythematosus (SLE). Methods. Clinical and serological data of 30 patients with juvenile-onset SLE (age at onset younger than 16 years old) were compared with data of 92 patients with adult-onset SLE. Symptoms occurring during the entire disease course were considered. Anti- P ribosomal antibodies were tested by ELISA. Results. Anti- P ribosomal antibodies were found significantly more often in pediatric-onset SLE patients (26.7% vs. 6.5%; OR = 5.21 [CI95% = 1.6-16.5], p = 0.003). Alopecia (OR = 10.11, CI 95% = 1.25-97) and skin rash (non discoid) (OR = 4.1, CI 95% = 1.25-13.89) were significantly associated with anti- P ribosomal antibodies. Conclusion. Anti-ribosomal P antibodies are more often found in patients with juvenile SLE. Alopecia and skin rash were the only clinical manifestations associated to anti-ribosomal P antibodies (AU)
Asunto(s)
Humanos , Masculino , Femenino , Niño , Adolescente , Adulto , Lupus Eritematoso Sistémico/complicaciones , Lupus Eritematoso Sistémico/epidemiología , Proteínas Ribosómicas/análisis , Proteínas Ribosómicas , Anticuerpos , Fosfoproteínas/análisis , Ensayo de Inmunoadsorción Enzimática/instrumentación , Ensayo de Inmunoadsorción Enzimática/métodos , Autoanticuerpos/análisis , Autoanticuerpos , Encuestas y Cuestionarios , Exantema/complicaciones , Trastornos por Fotosensibilidad/complicaciones , Alopecia/complicaciones , Eritema/complicaciones , Enfermedad de Raynaud/complicaciones , Serositis/complicaciones , Glomerulonefritis/complicaciones , Vasculitis/complicaciones , Síndrome de Sjögren/complicacionesRESUMEN
La poliangeítis con granulomatosis (GPA) es una enfermedad inflamatoria sistémica; los hallazgos histopatológicos incluyen necrosis tisular, formación de granulomas y vasculitis predominantemente devasos de pequeño y mediano calibre. Se caracteriza por la presencia en plasma de anticuerpos anti-citoplasma de neutrófilo dirigidos contra la proteinasa 3 (PR3-ANCA). La GPA comúnmente afecta la vía aérea superior, los pulmones y los riñones. El compromiso oftalmológico es una importante causa de morbilidad, ocurriendo aproximadamente en la mitad de los pacientes. La escleritis necrotizante (EN) es una manifestación infrecuente y grave de la GPA. Las complicaciones de la EN son la perforación ocular y pérdida de la visión. El tratamiento de inducción consiste en esteroides e inmunosupresores (ciclofosfamida o rituximab). El objetivo de este trabajo es describir 3 casos de GPA con EN como manifestación clínica rara y dominante.
Granulomatosis with polyangiitis (GPA) is a systemic inflammatory disease; histopathologic features often include necrosis, granulomaformation, and vasculitis of small-to-medium size vessels. Its characterizedby the presence of anti-neutrophil cytoplasm directedagainst proteinase 3 (PR3-ANCA). The GPA commonly affects the upperairways, lungs and kidneys. Ophthalmological involvement is animportant cause of morbidity in GPA, occurring in approximately inone-half of patients. Necrotizing scleritis is a rare and severe formof ocular manifestation in GPA. Complications are ocular perforationand loss of vision. Induction therapy involves steroids and immunosuppressants (cyclophosphamide or rituximab). The aim of this studyis to describe 3 cases of GPA with necrotizing scleritis as a rare anddominant clinical manifestation.
Asunto(s)
Humanos , Granulomatosis con Poliangitis , EscleritisRESUMEN
Antecedentes: Existen pocos estudios descriptivos sobre las causas de internación de los pacientes con vasculitis asociadas a ANCA (VAA), todos son retrospectivos y realizados en unidades de cuidados intensivos. Objetivo: Investigar la epidemiología, los hallazgos clínicos y la evolución de los pacientes con VAA durante su internación, e identificar los factores pronósticos asociados a mortalidad. Materiales y métodos: Se incluyeron los pacientes con diagnóstico de VAA internados en el Hospital Juan A. Fernández y la Clínica San Camilo (Ciudad Autónoma de Buenos Aires, Argentina), entre el 1 de enero de 2011 y el 31 de diciembre de 2013. Resultados: Treinta y cuatro pacientes fueron incluidos, 18 (53%) de sexo femenino. Edad media de 60 ± 12 años. En 9 (26%) pacientes el diagnóstico de VAA se realizó en la internación. La Poliangeítis Microscópica (MPA) fue la vasculitis más común (50%). Dieciocho (53%) pacientes se internaron por actividad clínica de la vasculitis. Órganos/sistemas afectados: pulmón (n=9), riñón (n=6), otorrinolaringológicas (n=5), sistema nervioso periférico (n=5) y piel (n=2). Ocho (23,5%) pacientes fueron admitidos por complicaciones infecciosas y ocho por otras causas. Fallecieron 8 (23,5%) pacientes, 3 debido a actividad de la vasculitis, 4 debido a complicaciones infecciosas y 1 por falla multiorgánica (2º infusión pamidronato). Los que ingresaron a UCI tuvieron mayor mortalidad (p=0,001); el sexo (p=0,69), la edad (p=0,15), el diagnóstico de novo de vasculitis (p=0,4), el BVAS y VDI no mostraron diferencias entre los sobrevivientes y fallecidos. La mortalidad de los pacientes que ingresaron por actividad de la vasculitis comparado con los que ingresaron por complicaciones infecciosas fue similar (p=0,6). Conclusiones: La causa más frecuente de internación en pacientes con VAA fue la actividad de la enfermedad, seguida por las causas infecciosas.
Background: Few retrospective studies have described the clinical course of patients with ANCA-asocciated vasculitis (AAV) admitted to the hospital, all of them in intensive care units (ICU).Objective: To study the epidemiology, clinical features and outcome of patients with AAV admitted to the hospital, and to identify the prognostic factors associated with mortality.Methods: Patients with AAV admitted to the Juan A. Fernández Hos-pital and San Camilo Clinic (Buenos Aires City, Argentina) betweenJanuary 2011 and December 2013 were included. Results: Thirty four patients [18 (53%) female] with an average 60 ±12 years old were included. AAV was diagnosed in 9 (26%) patientsin the hospital. Microscopic Polyangiitis was the most common AAV. Eighteen (53%) patients were admitted due to active vasculitis. Lung(n=9), kidney (n=6), ear-nose-throat (n=5), peripheral nervous system (n=5) and skin (n=2) were the organs/systems involved. Other reasons for admission were: infection and metabolic conditions [8(23.5%) patients each]. Eight (23.5%) patients died, 3 due to active vasculitis, 4 due to infection and 1 patient due to multiorgan failure after pamidronate treatment. Mortality was significantly higher for patients who were admitted in ICU (p=0.001); gender (p=0.69), age(p=0.15), new diagnosis of AAV (p=0.4), BVAS and VDI showed no significant differences between survival and dead patients. The mortality was similar (p=0.6) between the patients with active vasculitis and the patients with infections. Conclusion: The main reason for hospitalization in AAV patients was active vasculitis followed by infection. Mortality rate was high and the main causes were infections regardless the diagnosis at admission.
Asunto(s)
Servicio de Admisión en Hospital , Anticuerpos , Neutrófilos , VasculitisRESUMEN
El síndrome de activación macrofágica (SAM) es una entidad poco frecuente y grave, caracterizadapor una excesiva activación y proliferación de macrófagos y linfocitos T. Los factoresdesencadenantes son las infecciones, drogas, enfermedades malignas y autoinmunes. Ellupus eritematoso sistémico frecuentemente se asocia al SAM. En la práctica clínica, eldiagnóstico diferencial entre lupus eritematoso sistémico activo, SAM e infección es ungran desafío para el médico internista. Esto se debe a que los signos, síntomas y datos delaboratorio de estas entidades se superponen. El propósito de nuestro trabajo es el reportarlos casos de 2 pacientes con lupus eritematoso sistémico activo, SAM y sepsis...
Macrophage activation syndrome (MAS) is a rare and severe entity characterized by excessive activation and proliferation of macrophages and T-lymphocytes. The usual triggers are infections, drugs, malignancy and autoimmune diseases. Systemic lupus erythematosus is frequently associated with MAS. In clinical practice, differential diagnosis between active systemic lupus erythematosus, MAS and an infection is a great challenge for the internist. This happens because signs, symptoms and laboratory data from these illnesses overlap to a large degree. The purpose of this paper is to present a report on two patients with active systemic lupus erythematosus, MAS, and sepsis...
Asunto(s)
Humanos , Enfermedades Autoinmunes , Infecciones , Lupus Eritematoso SistémicoRESUMEN
Objetivo: Realizar una revisión de las biopsias de nervio y músculo de pacientes con sospecha clínica de neuropatía vasculítica y correlacionarlas con los datos clínicos, de laboratorio y electrofisiológicos. Materiales y métodos: Fueron revisadas retrospectivamente las historias clínicas de pacientes sometidos a biopsia de nervio/músculo debido a sospecha clínica de neuropatía vasculítica en el Hospital General de Agudos Juan A. Fernández de la Ciudad Autónoma de Buenos Aires entre los años 1999 y 2011. Resultados: Se incluyeron 13 pacientes, 8 (61,54 por ciento) de sexo femenino y 5 (38,46 por ciento) de sexo masculino; la edad media fue de 58,85 +/- 15,02 años. Dos tercios de los casos presentaron mononeuropatía múltiple al diagnóstico y en 9 de 12 casos el patrón electromiográfico fue axonal. La anatomía patológica del nervio mostró vasculitis definida en 6 casos (46,15 por ciento) y probable sólo en uno (7,69 por ciento), mientras que la biopsia de músculo evidenció vasculitis en el 90 por ciento de los casos (p=0,077). En el subgrupo de pacientes con diagnóstico definitivo de vasculitis sistémica primaria, el 100 por ciento de las biopsias de músculo y el 62,5 por ciento de las biopsias de nervio resultaron positivas para neuropatía vasculítica (NPV). Conclusiones: La biopsia de nervio es el único procedimiento aceptado actualmente para el diagnóstico definitivo de neuropatía vasculítica. La biopsia combinada de nervio y músculo mostró una clara tendencia, aunque no significativa, hacia una mayor utilidad diagnóstica de neuropatía vasculítica que la biopsia de nervio aislada. Consideramos que el estudio de un mayor número de casos contribuirá a aclarar esta duda.
Objective: To review the nerve and the muscle biopsies from patients with clinical suspicion of vasculitic neuropathy and their correlation with clinical, laboratory and electrophysiologic studies. Materials and methods: We retrospectively reviewed the medical records of patients undergoing nerve/muscle biopsy due to clinical suspicion of vasculitic neuropathy at the Juan A. Fernandez General Hospital in the city of Buenos Aires between 1999 and 2011. Results: Thirteen patients, 8 (61.54 percent) female and 5 (38.46 percent) male, mean age 58.85 +/- 15.02 years, were included. Two thirds of the patients had multiple mononeuropathy at diagnosis, and 9 of 12 cases had axonal pattern in the electromyogram. The histopathology of the nerve showed definite vasculitis in 6 cases (46.15 percent) and probable vasculitis in only one (7.69 percent), whereas muscle biopsy showed vasculitis in 90 percent of cases (p=0.077). In the subgroup of patients with definite diagnosis of primary systemic vasculitis, 100 percent of muscle biopsies and 62.5 percent of nerve biopsies were diagnostic of vasculitis neuropathy. Conclusion: Nerve biopsy in the only currently accepted procedure for definitive diagnosis of vasculitic neuropathy. The combined nerve and muscle biopsy showed a clear trend, but not statistically significant toward increased the diagnostic yield of vasculitis neuropathy that isolated nerve biopsy. A large number of cases will clarify this issue.
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano de 80 o más Años , Enfermedades del Sistema Nervioso Periférico/diagnóstico , Enfermedades del Sistema Nervioso Periférico/patología , Vasculitis/diagnóstico , Vasculitis/patología , BiopsiaRESUMEN
El Síndrome de Churg-Strauss es una vasculitis sistémica que afecta vasos de pequeño y mediano calibre y que suele presentarse con asma, fiebre, hipereosinofilia, insuficiencia cardiaca, daño renal y neuropatía periférica. esta última se observa en el 65 por ciento al 80 por ciento de los casos, siendo el compromiso de nervios craneales en una minoría, y aún más excepcional la parálisis de cuerdas vocales y el diafragma. Las neuropatías por vasculitis sistémicas pueden resultar en morbilidad grave e incluso la muerte, por esto la necesidad de instaurar un tratamiento temprano. Reportamos el caso de un paciente que padeció parálisis diafragmática y de cuerda vocal por síndrome de Churg-Strauss.
Churg-Strauss syndrome is a systemic vasculitis of the small and medium sized vessels that usually occurs with asthma, fever, hypereosinophilia, cardiac failure, renal damage and peripheral neuropathy. The latter affects 65 percent to 80 percent of patients, cranial nerves involvement is rare while vocal cord and diaphragmatic paralysis are exceptional. Neuropathies due to systemic vasculitis may result in significant disability and death, therefore the importance to institute an early treatment. We report here a patient who suffered diaphragmatic and vocal cord paralysis due to Churg-Strauss syndrome.